ReShape Lifesciences Ownership
| RSLS Stock | USD 0.66 0.04 5.71% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ReShape |
ReShape Stock Ownership Analysis
The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ReShape Lifesciences recorded earning per share (EPS) of 76.2. The entity last dividend was issued on the 25th of July 2019. The firm had 1:58 split on the 23rd of September 2024. ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. To find out more about ReShape Lifesciences contact Dan Gladney at 949 429 6680 or learn more at https://www.reshapelifesciences.com.Besides selling stocks to institutional investors, ReShape Lifesciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ReShape Lifesciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ReShape Lifesciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ReShape Lifesciences Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of ReShape Lifesciences are currently held by insiders. Unlike ReShape Lifesciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ReShape Lifesciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ReShape Lifesciences' insider trades
ReShape Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ReShape Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ReShape Lifesciences backward and forwards among themselves. ReShape Lifesciences' institutional investor refers to the entity that pools money to purchase ReShape Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 17.7 K | Tower Research Capital Llc | 2024-12-31 | 847 | Blackrock Inc | 2024-12-31 | 588 | Bank Of America Corp | 2024-12-31 | 6.0 | Group One Trading, Lp | 2024-12-31 | 2.0 | Atlantic Trust Group, Llc | 2024-12-31 | 1.0 |
ReShape Lifesciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ReShape Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ReShape Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ReShape Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.